Medtronic Installs GI Genius™ at 7 MNGI Locations

More than two dozen GI GeniusTM intelligent endoscopy modules active across seven MNGI Digestive Health clinics will improve the accuracy of colonoscopies for Minnesotans

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced the completed installation of 28 GI Genius™ intelligent endoscopy modules at seven MNGI Digestive Health clinics in the Twin Cities, Minnesota. MNGI Digestive Health is a leading gastroenterology practice specializing in gastrointestinal care and is the first practice offering AI-assisted colonoscopies, including those for colorectal cancer screening, in the Twin Cities.

“We know the value of an AI-assisted colonoscopy,” said Bob White, executive vice president and president of the Medical Surgical Portfolio for Medtronic. “I’m proud that Minnesotans will now join other patients across the country who have access to this life-transforming technology and proven polyp detection tool. Nationwide, over 51,000 individuals died from colorectal cancer in 2019; we are working to equip physicians and support patients in the fight against this deadly disease.”

The GI Genius intelligent endoscopy module, recently named to Fortune’s 2022 ‘Change the World’ list, is the first-to-market, computer-aided polyp detection system powered by artificial intelligence to detect colorectal polyps of varying shapes and sizes automatically in real time. This helps physicians detect polyps, which in turn can reduce the risk of colorectal cancer. Studies show that endoscopists with higher adenoma detection rates (ADR) during screening colonoscopy more effectively protect their patients from colorectal cancer. The GI Genius™ module has been shown to increase ADR by up to 14.4%. Each 1% increase in ADR decreases the risk of interval cancer by 3%.

The rate of new colorectal cancer cases (Per 100,000) in Minnesota was 33.9% in 2019, with 2,277 cases reported. When precancerous conditions are identified early by administering physicians, colorectal cancer can have a five-year survival rate of over 90%. In the validation study for GI Genius 2.0 software, using 338 colonoscopy video clips with confirmed polyps, the sensitivity for the GI Genius software for polyp identification was 100%.1, empowering physicians to detect colorectal polyps more efficiently, for better outcomes.

“Through our own internal pilot program, we saw the value of an AI-assisted colonoscopy,” said Scott R. Ketover, MD, AGAF, FASGE, President and CEO of MNGI Digestive Health. “Quality patient care is a priority for our practice and we quickly committed to a full implementation of this life-saving technology at all of MNGI’s Endoscopy Centers.” Ketover continued by saying, “MNGI Digestive Health gastroenterologists consistently have Adenoma Detection Rate (ADR) even higher than the targets suggested by the American Society of Gastrointestinal Endoscopy (ASGE). In fact, based on 2021 data, MNGI’s ADR was 61.50% for males as compared to the ASGE benchmark of 30%. MNGI’s ADR was 49.50% for females as compared to the ASGE benchmark of 20%. During our first three month pilot with the GI Genius™ device, 13 gastroenterologists at one ASC location experienced quality measurements that were enhanced and improved with a 17% increase in ADR. Companywide, we expect our 2022 data and future data to be similar, potentially saving even more lives.”

“We are honored to provide a groundbreaking, innovative practice such as MNGI Digestive Health with the cutting-edge AI-assisted technology to help physicians provide the best gastrointestinal care possible,” said Giovanni Di Napoli, president of the Gastrointestinal business, which is part of the Medical Surgical Portfolio at Medtronic. “Healthcare technology’s impact is only as large as it’s availability. We continue to work tirelessly to ensure patients nationwide have access to AI-assisted technology.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”